Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc., incorporated in 1992, has established its headquarters in San Diego, California. Focused on the areas of neuroscience and endocrine, Neurocrine Biosciences is engaged in the discovery, development, and commercialization of therapeutics for neurological and endocrine-related diseases and disorders. Prominent in its portfolio is Ingrezza® (valbenazine), a treatment designed for adults with tardive dyskinesia, and Ongentys® (opicapone), which serves as a catechol-O-methyltransferase inhibitor for Parkinson's disease patients on levodopa therapy. The company's main market is the United States; however, it also actively markets its products on an international scale. The presence of Neurocrine Biosciences' products in international markets is subject to expansion and changes in its global marketing and sales strategies, including possible partnerships and distribution agreements in various countries. (Powered by AI)